Jorge Hernando

1.2k total citations · 1 hit paper
55 papers, 581 citations indexed

About

Jorge Hernando is a scholar working on Oncology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Jorge Hernando has authored 55 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 25 papers in Epidemiology and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Jorge Hernando's work include Neuroendocrine Tumor Research Advances (25 papers), Lung Cancer Research Studies (20 papers) and Neuroblastoma Research and Treatments (11 papers). Jorge Hernando is often cited by papers focused on Neuroendocrine Tumor Research Advances (25 papers), Lung Cancer Research Studies (20 papers) and Neuroblastoma Research and Treatments (11 papers). Jorge Hernando collaborates with scholars based in Spain, Palestinian Territory and United States. Jorge Hernando's co-authors include Jaume Capdevila, Jaume Capdevila, Marcia S. Brose, Josep Tabernero, Steven I. Sherman, Ana O. Hoff, Jennifer Oliver, Erika Hitre, Jolanta Krajewska and Bruce Robinson and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jorge Hernando

48 papers receiving 576 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

2021 156 citations Marcia S. Brose, Bruce Robinson et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jorge Hernando Spain	11	305	204	159	142	107	55	581
Ying‐Hsia Chu United States	14	119 0.4×	208 1.0×	58 0.4×	147 1.0×	22 0.2×	26	492
Paola Concolino Italy	13	109 0.4×	119 0.6×	79 0.5×	307 2.2×	53 0.5×	41	516
Marı́a Niveiro Spain	11	134 0.4×	123 0.6×	46 0.3×	80 0.6×	11 0.1×	35	413
Sun Wook Han South Korea	12	195 0.6×	50 0.2×	37 0.2×	110 0.8×	11 0.1×	39	393
Rebecca Brown United States	9	59 0.2×	200 1.0×	56 0.4×	80 0.6×	13 0.1×	14	325
Fan Lin United States	12	176 0.6×	72 0.4×	96 0.6×	93 0.7×	6 0.1×	20	411
Yasuyoshi Sato Japan	11	187 0.6×	55 0.3×	28 0.2×	75 0.5×	19 0.2×	47	380
Eva Sigstad Norway	14	86 0.3×	261 1.3×	141 0.9×	37 0.3×	8 0.1×	21	508
Awatif Jamal Saudi Arabia	10	41 0.1×	38 0.2×	102 0.6×	124 0.9×	20 0.2×	23	366
Takachika Ozawa Japan	13	118 0.4×	18 0.1×	45 0.3×	87 0.6×	34 0.3×	28	417

Countries citing papers authored by Jorge Hernando

Since Specialization

Citations

This map shows the geographic impact of Jorge Hernando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Hernando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Hernando more than expected).

Fields of papers citing papers by Jorge Hernando

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Hernando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Hernando. The network helps show where Jorge Hernando may publish in the future.

Co-authorship network of co-authors of Jorge Hernando

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Hernando. A scholar is included among the top collaborators of Jorge Hernando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Hernando. Jorge Hernando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). DIGITAL.CSIC (Spanish National Research Council (CSIC)).

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research. 31(22). 4655–4663.

Strosberg, Jonathan, Rachel P. Riechelmann, Jorge Hernando, et al.. (2025). Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents.. Journal of Clinical Oncology. 43(4_suppl). 662–662. 2 indexed citations

García‐Rostán, Ginesa, et al.. (2025). Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 199(3). 228–238. 2 indexed citations

Martínez, María Carmen Riesco, Jaume Capdevila, Vicente Alonso, et al.. (2024). Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nature Communications. 15(1). 6753–6753. 10 indexed citations

Alonso‐Gordoa, Teresa, Paula Jiménez‐Fonseca, Javier Martínez‐Trufero, et al.. (2024). SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023). Clinical & Translational Oncology. 26(11). 2902–2916. 1 indexed citations

Capdevila, Jaume, Ismael Macías, Ignacio Escobar, et al.. (2023). Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. Journal of Clinical Oncology. 41(16_suppl). TPS3624–TPS3624.

Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359. 6 indexed citations

Arqués, Oriol, Irene Chicote, Lorena Ramírez, et al.. (2023). DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype. Cell Reports. 42(8). 112927–112927. 4 indexed citations

10.

Clavé, Sergi, Marta Sesé, Rosa Somoza, et al.. (2023). 2223P Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer. Annals of Oncology. 34. S1145–S1146. 1 indexed citations

11.

Cives, Mauro, Jorge Hernando, Ángela Lamarca, et al.. (2022). The impact of COVID‐19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients. Journal of Neuroendocrinology. 34(10). e13196–e13196. 2 indexed citations

12.

Grande, Enrique, Cristina Rodríguez‐Antona, Carlos López, et al.. (2021). Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. The Oncologist. 26(11). 941–949. 16 indexed citations

13.

Brose, Marcia S., Bruce Robinson, Steven I. Sherman, et al.. (2021). Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 22(8). 1126–1138. 156 indexed citations breakdown →

14.

Verdaguer, Helena, Elvira Buxó, N. Saoudi Gonzalez, et al.. (2020). 1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations. Annals of Oncology. 31. S951–S951. 1 indexed citations

15.

Grande, Enrique, Rafael Serrano del Rosal, Teresa Alonso, et al.. (2020). 1174P RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study. Annals of Oncology. 31. S777–S778. 1 indexed citations

16.

Hernando, Jorge, Mimi I. Hu, Eric J. Sherman, et al.. (2020). 1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). Annals of Oncology. 31. S1091–S1091. 3 indexed citations

17.

Capdevila, Jaume, Ignacio Matos, Francesco M. Mancuso, et al.. (2019). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics. 19(1). 312–317. 10 indexed citations

18.

Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909. 28 indexed citations

19.

Matos, Ignacio, et al.. (2017). The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Targeted Oncology. 12(6). 757–774. 1 indexed citations

20.

Barrientos, Rafael, et al.. (2003). Influencia de una embalse sobre la distribución y alimentación de la nutria (Lutra lutra L.) en el río Riaza (Segovia). 15(1). 81–90. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact